Strategies used for MUC1 immunotherapy: human clinical studies

References

• Apostolopoulos V, Hu XF, Pouniotis DS, Xing PX .MUC1: a molecule of many talents.Curr. Trends Immunol.12, 629–639 (2003).
   Google Scholar
• Apostolopoulos V, McKenzie IF, Pietersz GA. Breast cancer immunotherapy: current status and future prospects. Immunol. Cell Biol.74(5), 457–464 (1996).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr. Opin. Mol. Ther.1(1), 98–103 (1999).
   PubMed Web of Science ®Google Scholar
• McKenzie IF, Apostolopoulos V, Plebanski M, Pietersz GA, Loveland BE. Aspects of cancer immunotherapy. Immunol. Cell Biol.81(1), 79–85 (2003).
   PubMed Web of Science ®Google Scholar
• Itoh Y, Kamata-Sakurai M, Denda-Nagai K et al. Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin. Glycobiology18(1), 74–83 (2008).
   PubMed Web of Science ®Google Scholar
• McGuckin MA. CD227 (MUC1) – summary and workshop report. In: Leucocyte Typing VII. Mason D (Ed.). Oxford University Press, Oxford, UK, 54–56 (2001).
   Google Scholar
• Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res.68(7), 2419–2426 (2008).
   PubMed Web of Science ®Google Scholar
• Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev. Vaccines4(4), 493–502 (2005).
   PubMed Web of Science ®Google Scholar
• Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol.82, 249–293 (2004).
   PubMed Web of Science ®Google Scholar
• Tang C-K, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev. Vaccines7(7), 951–962 (2008).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, McKenzie IF. Studies of MUC1 peptides. In: Peptide Based Cancer Vaccines. Medical Intelligence Unit Series. Kast MW (Ed.). Landes Bioscience, Chapman and Hall, London, UK 106–120 (2000).
   Google Scholar
• Xing PX, Michael M, Apostolopoulos V et al. Phase I study of synthetic MUC1 peptides in breast cancer. Int. J. Oncol.6, 1283–1289 (1995).
   PubMed Web of Science ®Google Scholar
• Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res.63(1), 298–304 (1996).
   PubMed Web of Science ®Google Scholar
• Reddish M, MacLean GD, Koganty RR et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer76(6), 817–823 (1998).
   PubMed Web of Science ®Google Scholar
• Karanikas V, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest.100(11), 2783–2792 (1997).
   PubMed Web of Science ®Google Scholar
• van Leeuwen EB, Cloosen S, Senden-Gijsbers BL et al. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector. Cytotherapy8(1), 24–35 (2006).
   PubMed Web of Science ®Google Scholar
• van Leeuwen EB, Cloosen S, Senden-Gijsbers BL, Germeraad WT, Bos GM. Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC. Cytotherapy8(1), 36–46 (2006).
   PubMed Web of Science ®Google Scholar
• Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother.50(8), 397–407 (2001).
   PubMed Web of Science ®Google Scholar
• Maruyama K, Akiyama Y, Nara-Ashizawa N et al. Adenovirus-mediated MUC1 gene transduction into human blood-derived dendritic cells. J. Immunother.24(4), 345–353 (2001).
   PubMed Web of Science ®Google Scholar
• Pecher G, Spahn G, Schirrmann T et al. Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus. Anticancer Res.21(4A), 2591–2596 (2001).
   PubMed Web of Science ®Google Scholar
• Koido S, Hara E, Homma S et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res.11(21), 7891–7900 (2005).
   PubMedGoogle Scholar
• Koido S, Hara E, Homma S et al. Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J. Immunol.179(7), 4874–4883 (2007)
   PubMedGoogle Scholar
• Napoletano C, Rughetti A, Agervig Tarp MP et al. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res.67(17), 8358–8367 (2007).
   PubMedGoogle Scholar
• Apostolopoulos V. Methods of delivery to antigen-presenting cells: development of new and improved vaccines. Mol. Pharm.4(1), 1–3 (2007).
   Google Scholar
• Pietersz GA, Pouniotis DS, Apostolopoulos V. Design of peptide-based vaccines for cancer. Curr. Med. Chem.13(14), 1591–1607 (2006).
   PubMed Web of Science ®Google Scholar
• Proudfoot O, Apostolopoulos V, Pietersz GA. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol. Pharm.4(1), 58–72 (2007).
   PubMedGoogle Scholar
• Tang C-K, Sheng K-C, Apostolopoulos V, Pietersz GA. Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors. Expert Rev. Vaccines7(7), 1005–1018 (2008).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine18(27), 3174–3184 (2000).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr. Mol. Med.1(4), 469–474 (2001).
   PubMedGoogle Scholar
• Apostolopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur. J. Immunol.27(10), 2579–2587 (1997).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol.159(11), 5211–5218 (1997).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF. CTL in mice immunized with human mucin 1 are MHC-restricted. J. Immunol.155(11), 5089–5094 (1995).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, McKenzie IF, Lees C, Matthaei KI, Young IG. A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo. Eur. J. Immunol.30(6), 1733–1739 (2000).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, McKenzie IF, Pietersz GA. Generation of MUC1 cytotoxic T-cells in mice and epitope mapping. Methods Mol. Biol.125, 455–462 (2000).
   PubMedGoogle Scholar
• Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl Acad. Sci. USA92(22), 10128–10132 (1995).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine14(9), 930–938 (1996).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Popovski V, McKenzie IF. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1–mannan fusion protein (M-FP). J. Immunother.21(2), 109–113 (1998).
   Google Scholar
• Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J. Mol. Biol.318(5), 1293–1305 (2002).
   PubMed Web of Science ®Google Scholar
• Lees CJ, Apostolopoulos V, Acres B, Ong CS, Popovski V, McKenzie IF. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan–MUC1. Cancer Immunol. Immunother.48(11), 644–652 (2000).
   PubMed Web of Science ®Google Scholar
• Lees CJ, Apostolopoulos V, Acres B et al. Immunotherapy with mannan–MUC1 and IL-12 in MUC1 transgenic mice. Vaccine19(2–3), 158–162 (2000).
   PubMed Web of Science ®Google Scholar
• Lees CJ, Apostolopoulos V, McKenzie IF. Cytokine production from murine CD4 and CD8 cells after mannan–MUC1 immunization. J. Interferon Cytokine Res.19(12), 1373–1379 (1999).
   PubMed Web of Science ®Google Scholar
• Lofthouse SA, Apostolopoulos V, Pietersz GA, Li W, McKenzie IF. Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Vaccine15(14), 1586–1593 (1997).
   PubMed Web of Science ®Google Scholar
• McKenzie IF, Apostolopoulos V, Lees C et al. Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. Vet. Immunol. Immunopathol.63(1–2), 185–190 (1998).
   PubMed Web of Science ®Google Scholar
• Pietersz GA, Li W, Popovski V, Caruana JA, Apostolopoulos V, McKenzie IF. Parameters for using mannan–MUC1 fusion protein to induce cellular immunity. Cancer Immunol. Immunother.45(6), 321–326 (1998).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde–mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur. J. Immunol.30(6), 1714–1723 (2000).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Yuriev E, Ramsland PA et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl Acad. Sci. USA100(25), 15029–15034 (2003).
   PubMed Web of Science ®Google Scholar
• Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin. Cancer Res.6(3), 829–837 (2000).
   PubMed Web of Science ®Google Scholar
• Karanikas V, Thynne G, Mitchell P et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J. Immunother.24(2), 172–183 (2001).
   Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, Tsibanis A et al. Pilot Phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan–MUC1 [ISRCTN71711835]. Breast Cancer Res.8(3), R27 (2006).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Matsoukas J, Plebanski M, Mavromoustakos T. Applications of peptide mimetics in cancer. Curr. Med. Chem.9(4), 411–420 (2002).
   Google Scholar
• Apostolopoulos V, Lofthouse SA, Popovski V, Chelvanayagam G, Sandrin MS, McKenzie IF. Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nat. Biotechnol.16(3), 276–280 (1998).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive Gal a(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med.4(3), 315–320 (1998).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Sandrin MS, McKenzie IF. Mimics and cross reactions of relevance to tumour immunotherapy. Vaccine18(3–4), 268–275 (1999).
   PubMedGoogle Scholar
• Apostolopoulos V, Sandrin MS, McKenzie IF. Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy. J. Mol. Med.77(5), 427–436 (1999).
   Google Scholar
• Loveland BE, Zhao A, White S et al. Mannan–MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin. Cancer Res.12(3 Pt 1), 869–877 (2006).
   PubMed Web of Science ®Google Scholar
• Brossart P. Dendritic cells in vaccination therapies of malignant diseases. Transfus. Apher. Sci.27(2), 183–186 (2002).
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood96(9), 3102–3108 (2000).
   PubMed Web of Science ®Google Scholar
• Wierecky J, Mueller M, Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol. Immunother.55(1), 63–67 (2006).
   PubMed Web of Science ®Google Scholar
• Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res.66(11), 5910–5918 (2006).
   PubMed Web of Science ®Google Scholar
• Kontani K, Taguchi O, Ozaki Y et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int. J. Mol. Med.12(4), 493–502 (2003).
   PubMed Web of Science ®Google Scholar
• Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol. Immunother.51(11–12), 669–673 (2002).
   PubMed Web of Science ®Google Scholar
• Sheng KC, Pietersz GA, Wright MD, Apostolopoulos V. Dendritic cells: activation and maturation – applications for cancer immunotherapy. Curr. Med. Chem.12(15), 1783–1800 (2005).
   PubMed Web of Science ®Google Scholar
• Kondo H, Hazama S, Kawaoka T et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res.28(1B), 379–387 (2008).
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Calderwood SK. Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev. Vaccines7(7), 1055–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Avigan D. Dendritic cell–tumor fusion vaccines for renal cell carcinoma. Clin. Cancer Res.10(18 Pt 2), 6347S–6352S (2004).
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res.10(14), 4699–4708 (2004).
   PubMed Web of Science ®Google Scholar
• Chang GC, Lan HC, Juang SH et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer103(4), 763–771 (2005).
   PubMed Web of Science ®Google Scholar
• Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res.6(5), 1693–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer97(5), 660–667 (2002).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Lee KM, McKolanis J et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother.54(3), 254–264 (2005).
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ueno T, Kawaoka T et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res.25(5), 3575–3579 (2005).
   PubMed Web of Science ®Google Scholar
• Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clinical Lung Cancer3(1), 49–57 (2001).
   PubMedGoogle Scholar
• Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol.23(27), 6674–6681 (2005).
   PubMed Web of Science ®Google Scholar
• North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J. Urol.176(1), 91–95 (2006).
   PubMed Web of Science ®Google Scholar
• Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin. Cancer Res.13(15 Pt 2), S4652–S4654 (2007).
   PubMed Web of Science ®Google Scholar
• Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin. Biol. Ther.7(11), 1723–1730 (2007).
   PubMed Web of Science ®Google Scholar
• Acres B, Apostolopoulos V, Balloul JM et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol. Immunother.48(10), 588–594 (2000).
   PubMed Web of Science ®Google Scholar
• Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother.23(5), 570–580 (2000).
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med.5(8), 690–699 (2003).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, van Ophoven A, Gitlitz BJ et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J. Immunother.27(3), 240–253 (2004).
   PubMed Web of Science ®Google Scholar
• Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines7(7), 889–893 (2008).
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin. Biol. Ther.7(4), 543–554 (2007).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim-Schulze S, Manson K et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med.5, 60 (2007).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res.14(10), 3060–3069 (2008).
   PubMed Web of Science ®Google Scholar
• Hird V, Maraveyas A, Snook D et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer68(2), 403–406 (1993).
   PubMed Web of Science ®Google Scholar
• Hughes OD, Bishop MC, Perkins AC et al. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J. Clin. Oncol.18(2), 363–370 (2000).
   Google Scholar
• Nicholson S, Bomphray CC, Thomas H et al. A Phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother.53(9), 809–816 (2004).
   PubMed Web of Science ®Google Scholar
• Vaughan HA, Ho DW, Karanikas V, Sandrin MS, McKenzie IF, Pietersz GA. The immune response of mice and cynomolgus monkeys to macaque mucin 1–mannan. Vaccine18(28), 3297–3309 (2000).
   PubMed Web of Science ®Google Scholar
• Vaughan HA, Ho DW, Karanikas VA et al. Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan–human MUC1 conjugates. Vaccine17(20–21), 2740–2752 (1999).
   PubMed Web of Science ®Google Scholar
• Xing PX, Apostolopoulos V, Karkaloutsos J, McKenzie IF. Monoclonal antibodies to mucin VNTR peptides. Methods Mol. Biol.125, 369–381 (2000).
   Google Scholar
• Xing PX, Apostolopoulos V, Pietersz G, McKenzie IF. Anti-mucin monoclonal antibodies. Front. Biosci.6, D1284–D1295 (2001).
   Google Scholar
• Xing PX, Lees C, Lodding J et al. Mouse mucin 1 (MUC1) defined by monoclonal antibodies. Int. J. Cancer76(6), 875–883 (1998).
   PubMed Web of Science ®Google Scholar
• Jerome KR, Kirk AD, Pecher G, Ferguson WW, Finn OJ. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol. Immunother.43(6), 355–360 (1997).
   PubMed Web of Science ®Google Scholar
• Palmer DC, Chan CC, Gattinoni L et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers sever ocular autoimmunity. Proc. Natl Acad. Sci. USA105(23), 8061–8066 (2008).
   PubMed Web of Science ®Google Scholar
• von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol.18(3), 574–583 (2000).
   PubMed Web of Science ®Google Scholar
• Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol.155(10), 4766–4774 (1995).
   PubMed Web of Science ®Google Scholar
• Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell. Immunol.194(2), 143–149 (1999).
   PubMed Web of Science ®Google Scholar
• Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine18(19), 2059–2071 (2000).
   Google Scholar
• Sheng KC, Kalkanidis M, Pouniotis DS et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol.38(2), 424–436 (2008).
   PubMed Web of Science ®Google Scholar
• Sheng KC, Pouniotis DS, Wright MD et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology118(3), 372–383 (2006).
   PubMed Web of Science ®Google Scholar
• Slovin SF, Ragupathi G, Fernandez C et al. A polyvalent vaccine for high-risk prostate patients: ‘are more antigens better?’ Cancer Immunol. Immunother.56(12), 1921–1930 (2007).
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit. Rev. Immunol.27(5), 451–462 (2007).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine25(Suppl. 2), B89–B96 (2007).
   PubMed Web of Science ®Google Scholar
• Holmberg LA, Oparin DV, Gooley T, Sandmaier BM. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin. Breast Cancer3(Suppl. 4), S144–S151 (2003).
   PubMedGoogle Scholar
• Holmberg LA, Sandmaier BM. Theratope vaccine (STn-KLH). Expert Opin. Biol. Ther.1(5), 881–891 (2001).
   PubMed Web of Science ®Google Scholar
• Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines3(6), 655–663 (2004).
   PubMedGoogle Scholar
• Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin. Breast Cancer3(Suppl. 4), S139–S143 (2003).
   Google Scholar
• Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer3(Suppl. 4), S134–S138 (2003).
   PubMed Web of Science ®Google Scholar